Prospects for Personalized Cardiovascular Medicine
Tóm tắt
Từ khóa
Tài liệu tham khảo
Mariadason, 2003, Microarray analysis in the clinical management of cancer, Hematol Oncol Clin North Am, 17, 377, 10.1016/S0889-8588(03)00006-6
Rees-Unwin, 2004, Proteomics and the haematologist, Clin Lab Haematol, 26, 77, 10.1111/j.1365-2257.2004.00598.x
Weston, 2004, Systems biology, proteomics, and the future of health care, J Proteome Res, 3, 179, 10.1021/pr0499693
Willard, 2005, Genomic medicine, Philos Trans R Soc Lond B Biol Sci, 360, 1543, 10.1098/rstb.2005.1683
Mooser, 2003, Cardiovascular pharmacogenetics in the SNP era, J Thromb Hemostasis, 1, 1398, 10.1046/j.1538-7836.2003.00272.x
Hauser, 2004, A genome wide scan for early-onset coronary artery disease in 438 families, Am J Hum Genet, 75, 436, 10.1086/423900
Wang, 2004, Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genome wide linkage analysis, Am J Hum Genet, 74, 262, 10.1086/381560
Pajukanta, 2000, Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland, Am J Hum Genet, 67, 1481, 10.1086/316902
Francke, 2001, A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27, Hum Mol Genet, 10, 2751, 10.1093/hmg/10.24.2751
Broeckel, 2002, A comprehensive linkage analysis for myocardial infarction and its related risk factors, Nat Genet, 30, 210, 10.1038/ng827
Harrap, 2002, Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2, Arterioscler Thromb Vasc Biol, 22, 874, 10.1161/01.ATV.0000016258.40568.F1
Helgadottir, 2004, The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke, Nat Genet, 36, 233, 10.1038/ng1311
Wang, 2003, Mutation of MEF2A in an inherited disorder with features of coronary artery disease, Science, 302, 1578, 10.1126/science.1088477
Topol, 2005, The genomic basis of myocardial infarction, J Am Coll Cardiol, 46, 1456, 10.1016/j.jacc.2005.06.064
Dixon, 1990, Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis, Nature, 343, 282, 10.1038/343282a0
Mehrabian, 2002, Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice, Circ Res, 91, 120, 10.1161/01.RES.0000028008.99774.7F
Spanbroek, 2003, Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis, Proc Natl Acad Sci U S A, 100, 1238, 10.1073/pnas.242716099
Dwyer, 2004, Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis, N Engl J Med, 350, 29, 10.1056/NEJMoa025079
Grody, 2001, American College of Medical Genetics consensus statement on factor V Leiden mutation testing, Genet Med, 3, 139, 10.1097/00125817-200103000-00009
Olson, 2002, Diagnostic issues in thrombophilia, Arch Pathol Lab Med, 126, 1277, 10.5858/2002-126-1277-COAPCC
Agerholm-Larsen, 2000, ACE gene polymorphism in cardiovascular disease, Arterioscler Thromb Vasc Biol, 20, 484, 10.1161/01.ATV.20.2.484
Keavney, 2000, Large-scale test of hypothesized associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5,000 cases and 6,000 controls, Lancet, 355, 434, 10.1016/S0140-6736(99)07192-5
Chiodini, 2003, APO B gene polymorphisms and coronary artery disease, Atherosclerosis, 167, 355, 10.1016/S0021-9150(02)00425-2
Boekholdt, 2001, Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction, Circulation, 104, 3063, 10.1161/hc5001.100793
Juhan-Vague, 1996, Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities, Circulation, 94, 2057, 10.1161/01.CIR.94.9.2057
Mansfield, 1995, Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus, Thromb Haemost, 74, 842, 10.1055/s-0038-1649834
Tybjaerg-Hansen, 1997, A common mutation (G-455→A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study, J Clin Invest, 99, 3034, 10.1172/JCI119499
Casas, 2004, Endothelial nitric oxide synthase genotype and ischemic heart disease, Circulation, 109, 1359, 10.1161/01.CIR.0000121357.76910.A3
Quyyumi, 1995, Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis, J Clin Invest, 95, 1747, 10.1172/JCI117852
Hingorani, 2001, Polymorphisms in endothelial nitric oxide synthase and atherogenesis, Atherosclerosis, 154, 521, 10.1016/S0021-9150(00)00699-7
McCarthy, 2004, Large scale association analysis for identification of genes underlying premature coronary heart disease, J Med Genet, 41, 334, 10.1136/jmg.2003.016584
Yamada, 2002, Prediction of the risk of myocardial infarction from polymorphisms in candidate genes, N Engl J Med, 347, 1916, 10.1056/NEJMoa021445
Boerma, 1999, A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development, J Intern Med, 246, 211, 10.1046/j.1365-2796.1999.00564.x
Yeh, 2001, Connexin37 gene polymorphism and coronary artery disease in Taiwan, Int J Cardiol, 81, 251, 10.1016/S0167-5273(01)00574-5
Kwak, 2002, Altered pattern of vascular connexin expression in atherosclerotic plaques, Arterioscler Thromb Vasc Biol, 22, 225, 10.1161/hq0102.104125
Azumi, 1999, Expression of NADH/NADPH oxidase p22phox in human coronary arteries, Circulation, 100, 1494, 10.1161/01.CIR.100.14.1494
Cahilly, 2000, A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis, Circ Res, 86, 391, 10.1161/01.RES.86.4.391
Ikeda, 2003, Matrix metalloproteinases and coronary artery diseases, Clin Cardiol, 26, 55, 10.1002/clc.4960260203
Tobin, 2004, Genotypes and haplotypes predisposing to myocardial infarction, Eur Heart J, 25, 459, 10.1016/j.ehj.2003.11.014
Medzhitov, 1997, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature, 388, 394, 10.1038/41131
Arbour, 2000, TLR4 mutations are associated with endotoxin hyporesponsiveness in humans, Nat Genet, 25, 187, 10.1038/76048
Ridker, 1997, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, 336, 973, 10.1056/NEJM199704033361401
Kiechl, 2002, Toll-like receptor 4 polymorphisms and atherogenesis, N Engl J Med, 347, 185, 10.1056/NEJMoa012673
Ozaki, 2002, Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction, Nat Genet, 32, 650, 10.1038/ng1047
Schreyer, 2002, Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice, J Biol Chem, 277, 12364, 10.1074/jbc.M111727200
Suzuki, 2004, LTA 252G allele containing haplotype block is associated with high serum C-reactive protein levels, Atherosclerosis, 176, 91, 10.1016/j.atherosclerosis.2003.12.013
Danziger, 2005, Discovering the genetics of complex disorders through integration of genomic mapping and transcriptional profiling, Curr Hypertens Rev, 1, 25, 10.2174/1573402052952771
Seo, 2004, Gene expression phenotypes of atherosclerosis, Arterioscler Thromb Vasc Biol, 24, 1922, 10.1161/01.ATV.0000141358.65242.1f
Davies, 2004, Molecular phenotypes of atherosclerosis, Arterioscler Thromb Vasc Biol, 24, 1746, 10.1161/01.ATV.0000144777.98578.9e
Liew, 2004, Molecular genetics and genomics of heart failure, Nat Rev Genet, 5, 811, 10.1038/nrg1470
Kittleson, 2005, Gene expression analysis of ischemic and nonischemic cardiomyopathy. Shared and distinct genes in the development of heart failure, Physiol Genomics, 21, 299, 10.1152/physiolgenomics.00255.2004
Koontz, 2005, Functional genomic study of post-operative atrial fibrillation using oligonucleotide microarrays
Horwitz, 2004, Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression, Circulation, 110, 3815, 10.1161/01.CIR.0000150539.72783.BF
Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study), Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9
Hamm, 1992, The prognostic value of serum troponin T in unstable angina, N Engl J Med, 327, 146, 10.1056/NEJM199207163270302
Ohman, 1996, Cardiac troponin T levels for risk stratification in acute myocardial ischemia, N Engl J Med, 335, 1333, 10.1056/NEJM199610313351801
Antman, 1996, Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes, N Engl J Med, 335, 1342, 10.1056/NEJM199610313351802
Ottani, 2000, Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes, Am Heart J, 140, 917, 10.1067/mhj.2000.111107
Heidenreich, 2001, The prognostic value of troponin in patients with non–ST-elevation acute coronary syndromes, J Am Coll Cardiol, 38, 478, 10.1016/S0735-1097(01)01388-2
Newby, 1998, Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes, Circulation, 98, 1853, 10.1161/01.CIR.98.18.1853
Hamm, 1999, Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels, N Engl J Med, 340, 1623, 10.1056/NEJM199905273402103
Heeschen, 1999, Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban, Lancet, 354, 1757, 10.1016/S0140-6736(99)10285-X
Newby, 2001, Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status, Circulation, 103, 2891, 10.1161/01.CIR.103.24.2891
Lindahl, 1997, Troponin T identifies patients with unstable angina who benefit from long-term anti-thrombotic protection, J Am Coll Cardiol, 29, 43, 10.1016/S0735-1097(96)00447-0
Morrow, 2000, Cardiac troponin I for the stratification for early outcomes and the efficacy of enoxaparin in unstable angina, J Am Coll Cardiol, 36, 1812, 10.1016/S0735-1097(00)00942-6
Morrow, 2001, Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non–ST-elevation myocardial infarction, JAMA, 286, 2405, 10.1001/jama.286.19.2405
Wallentin, 2000, Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease, Lancet, 356, 9, 10.1016/S0140-6736(00)02427-2
Boersma, 2002, Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes, Lancet, 359, 189, 10.1016/S0140-6736(02)07442-1
Glaser, 2002, Benefit of an early invasive management strategy in women with acute coronary syndromes, JAMA, 288, 3124, 10.1001/jama.288.24.3124
Antman, 2001, Troponin measurements in ischemic heart disease, J Am Coll Cardiol, 38, 987, 10.1016/S0735-1097(01)01497-8
Pearson, 2003, Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation, 107, 499, 10.1161/01.CIR.0000052939.59093.45
Pai, 2004, Inflammatory markers and the risk of coronary heart disease in men and women, N Engl J Med, 351, 2599, 10.1056/NEJMoa040967
Biasucci, 2004, CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to clinical and public health practice; clinical use of inflammatory markers in patient with cardiovascular diseases: a background paper, Circulation, 110, e560, 10.1161/01.CIR.0000148983.88334.80
Ridker, 2000, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med, 342, 836, 10.1056/NEJM200003233421202
Libby, 1999, Novel inflammatory markers of coronary risk, Circulation, 100, 1148, 10.1161/01.CIR.100.11.1148
Koenig, 1999, C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially health middle-aged men, Circulation, 99, 237, 10.1161/01.CIR.99.2.237
Danesh, 2004, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N Engl J Med, 350, 1387, 10.1056/NEJMoa032804
Ikonomidis, 1999, Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin, Circulation, 100, 793, 10.1161/01.CIR.100.8.793
Ridker, 2004, Established and emerging plasma biomarkers in the prediction of first atherothrombotic events, Circulation, 109, IV6, 10.1161/01.CIR.0000133444.17867.56
Ridker, 2004, Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores, Circulation, 109, 1955, 10.1161/01.CIR.0000125690.80303.A8
Ridker, 1999, Long-term effects of pravastatin on plasma concentration of C-reactive protein, Circulation, 100, 230, 10.1161/01.CIR.100.3.230
Willerson, 2004, Inflammation as a cardiovascular risk factor, Circulation, 109, II2, 10.1161/01.CIR.0000129535.04194.38
Ridker, 2005, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) C-reactive protein levels and outcomes after statin therapy, N Engl J Med, 352, 20, 10.1056/NEJMoa042378
Ridker, 1997, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, 336, 973, 10.1056/NEJM199704033361401
Smith, 2004, CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to clinical and public health practice: report from the Clinical Practice Discussion Group, Circulation, 110, e550, 10.1161/01.CIR.0000148981.71644.C7
Ridker, 1998, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels, Circulation, 98, 839, 10.1161/01.CIR.98.9.839
Albert, 2001, Effect of statin therapy of C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study, JAMA, 286, 64, 10.1001/jama.286.1.64
Ridker, 2001, Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia, Circulation, 103, 1191, 10.1161/01.CIR.103.9.1191
Jialal, 2001, Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels, Circulation, 103, 1933, 10.1161/01.CIR.103.15.1933
Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, 344, 1959, 10.1056/NEJM200106283442601
Ridker, 2003, Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein, Circulation, 108, 2292, 10.1161/01.CIR.0000100688.17280.E6
Heeschen, 2004, Prognostic value of placental growth factor in patients with acute chest pain, JAMA, 291, 435, 10.1001/jama.291.4.435
Morrow, 1998, C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes, J Am Coll Cardiol, 31, 1460, 10.1016/S0735-1097(98)00136-3
Lindahl, 2000, Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease, N Engl J Med, 343, 1139, 10.1056/NEJM200010193431602
Lindmark, 2001, Relationship between interleukin-6 and mortality in patients with unstable coronary artery disease, JAMA, 286, 2107, 10.1001/jama.286.17.2107
Varo, 2003, Soluble CD40L. Risk prediction after acute coronary syndromes, Circulation, 108, r43, 10.1161/01.CIR.0000088521.04017.13
Heeschen, 2003, Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes, Circulation, 107, 2109, 10.1161/01.CIR.0000065232.57371.25
Brennan, 2003, Prognostic value of myeloperoxidase in patients with chest pain, N Engl J Med, 349, 1595, 10.1056/NEJMoa035003
de Lemos, 2003, Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes, Circulation, 107, 327, 10.1161/01.CIR.0000049742.68848.99
Szmitko, 2003, New markers of inflammation and endothelial cell activation, Circulation, 108, 1917, 10.1161/01.CIR.0000089190.95415.9F
Sabatine, 2002, Multimarker approach to risk stratification in non–ST-elevation acute coronary syndromes. Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide, Circulation, 105, 1760, 10.1161/01.CIR.0000015464.18023.0A
Baldus, 2003, Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes, Circulation, 108, 1440, 10.1161/01.CIR.0000090690.67322.51
Heeschen, 2005, Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes, J Am Coll Cardiol, 45, 229, 10.1016/j.jacc.2004.09.060
Heeschen, 2003, Soluble CD40 ligand in acute coronary syndromes, N Engl J Med, 348, 1104, 10.1056/NEJMoa022600
McCullough, 2002, B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure, Circulation, 106, 416, 10.1161/01.CIR.0000025242.79963.4C
Maisel, 2004, Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath, J Am Coll Cardiol, 44, 1328, 10.1016/j.jacc.2004.06.015
Maisel, 2002, Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N Engl J Med, 347, 161, 10.1056/NEJMoa020233
Omland, 2005, B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease, Am J Cardiol, 95, 24, 10.1016/j.amjcard.2004.08.058
Kragelund, 2005, N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease, N Engl J Med, 352, 666, 10.1056/NEJMoa042330
Wang, 2004, Plasma natriuretic peptide levels and the risk of cardiovascular events and death, N Engl J Med, 350, 655, 10.1056/NEJMoa031994
Jernberg, 2002, N-Terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation, J Am Coll Cardiol, 40, 437, 10.1016/S0735-1097(02)01986-1
de Lemos, 2001, The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes, N Engl J Med, 345, 1014, 10.1056/NEJMoa011053
Sabatine, 2004, Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia, J Am Coll Cardiol, 44, 1988, 10.1016/j.jacc.2004.07.057
Tapanainen, 2004, Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era, J Am Coll Cardiol, 43, 757, 10.1016/j.jacc.2003.09.048
Morrow, 2003, Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non–ST-elevation myocardial infarction, J Am Coll Cardiol, 41, 1264, 10.1016/S0735-1097(03)00168-2
Newby, 2001, Bedside multimarker testing for risk stratification in chest pain units, Circulation, 103, 1832, 10.1161/01.CIR.103.14.1832
Donahue, 2004, Proteomic discovery of coronary artery disease proteins using industrial scale analysis of pooled plasma, Circulation, 110, III212
Granger, 2004, National Heart, Lung and Blood Institute Clinical Proteomics Working Group report, Circulation, 109, 1697, 10.1161/01.CIR.0000121563.47232.2A
Metabolomics: Application to Environmental Health Research. Available at: http://grants.nih.gov/grants/guide/rfa-files/RFA-ES-04-008.html. Accessed September 13, 2005.
Human Metabolome Project. Available at: http://www.metabolomics.ca. Accessed September 13, 2005.
Narayanan, 2001, Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells, Int J Oncol, 19, 1255
Narayanan, 2003, Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells, Cancer Res, 63, 972
Berger, 2002, Dietary effects of arachidonate-rich fungal oil and fish oil on murine hepatic and hippocampal gene expression, Lipids Health Dis, 1, 2, 10.1186/1476-511X-1-2
Puskas, 2003, Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus, Proc Natl Acad Sci U S A, 100, 1580, 10.1073/pnas.0337683100
Watkins, 2002, Lipid metabolime-wide effects of the peroxisome proliferator-activated receptor gamma agonist rosiglitazone, J Lipid Res, 43, 1809, 10.1194/jlr.M200169-JLR200
Brindle, 2002, Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using UP1H-NMR-based metabonomics, Nature Med, 8, 1439, 10.1038/nm1202-802
Watkins, 2002, Toward the implementation of metabolomic assessments of human health and nutrition, Curr Opin Biotechnol, 13, 512, 10.1016/S0958-1669(02)00363-4
Chasman, 2004, Pharmacogenetic study of statin therapy and cholesterol reduction, JAMA, 291, 2821, 10.1001/jama.291.23.2821
Herrington, 2002, Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease, N Engl J Med, 346, 967, 10.1056/NEJMoa012952
Bianchi, 1994, Two point mutations within the adducin genes are involved in blood pressure variation, Proc Natl Acad Sci U S A, 91, 3999, 10.1073/pnas.91.9.3999
Manunta, 1998, Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients, Kidney Int, 53, 1471, 10.1046/j.1523-1755.1998.00931.x
Psaty, 2000, Association of the alpha-adducin polymorphism with blood pressure and risk of myocardial infarction, J Hum Hypertens, 14, 95, 10.1038/sj.jhh.1000943
Psaty, 2002, Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension, JAMA, 287, 1680, 10.1001/jama.287.13.1680
Hunt, 2002, ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult, J Heart Lung Transplant, 21, 189, 10.1016/S1053-2498(01)00776-8
Mialet, 2003, Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure, Nat Med, 9, 1300, 10.1038/nm930
Liggett, 2004, BEST Substudy
McNamara, 2001, Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure, Circulation, 103, 1644, 10.1161/01.CIR.103.12.1644
McNamara, 2004, Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure, J Am Coll Cardiol, 44, 2019, 10.1016/j.jacc.2004.08.048
Schwartz, 1993, Diagnostic criteria for the long QT syndrome. An update, Circulation, 88, 782, 10.1161/01.CIR.88.2.782
Schwartz, 2001, Genotype-phenotype correlation in the long-QT syndrome, Circulation, 103, 89, 10.1161/01.CIR.103.1.89
Benhorin, 2000, Effects of flecainide in patients with new SCN5A mutation, Circulation, 101, 1698, 10.1161/01.CIR.101.14.1698
Higashi, 2002, Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy, JAMA, 287, 1690, 10.1001/jama.287.13.1690
U.S. Food and Drug Administration. Genomics at FDA. Available at: http://www.fda.gov/cder/genomics/default.htm. Accessed September 13, 2005.
MacNeill, 2004, Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease, J Am Coll Cardiol, 44, 972, 10.1016/j.jacc.2004.05.066
Tsimikas, 1999, Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo, J Nucl Cardiol, 6, 41, 10.1016/S1071-3581(99)90064-8